logo
  

Senior Plc Acquires Lymington Precision Engineering - Quick Facts

Senior plc (SNR.L) announced it has acquired 100% of the issued share capital of Lymington Precision Engineering Limited, from management and Vine Street Capital, for an initial consideration of 45.8 million pounds on a debt free/cash free basis. Additional earn-out consideration of up to 31.7 million pounds is potentially payable, dependent upon the financial performance of LPE during the 12 month period ending 31 March 2016.

LPE is a leading manufacturer of precision-machined components, fabrications, assemblies and kit sets for the oil and gas, telecommunications, aerospace, defence, land and sea systems, nuclear and marine industries. The company is based in Lymington, Hampshire, UK. LPE will form part of Senior's Flexonics Division.

Senior plc said, due to the current short-term uncertainties in the oil and gas market, its financial performance is expected to be materially lower over the next twelve months than that experienced in the recent past. The Group also said the acquisition is still expected to be immediately earnings enhancing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT